Orano Med lays foundations for new manufacturing site for the production of lead-212 radioligand therapies

Orano Med (a subsidiary of the Orano Group), a pioneer in the development of targeted alpha therapies for oncology, today laid the foundation stone for its ATLab (Alpha Therapy Laboratory) in Onnaing (France, 59). This will be Europe's first industrial-scale pharmaceutical facility dedicated to the production of lead-212 based radioligand therapies.

The ground-breaking ceremony was attended by Xavier Jouanin, Mayor of Onnaing, Laurent Degallaix, President of Valenciennes Métropole and Mayor of Valenciennes, Aurore Colson, Regional Councillor for the Circular Economy, Lise Alter, Managing Director of the French Health Innovation Agency (AIS - Agence de l'Innovation en santé), Guillaume Dureau, Senior Executive Vice-President Projects & Innovation R&D and Nuclear Medicine for the Orano Group, Julien Dodet, CEO of Orano Med, and Guillaume Quenet, sub-prefect of Valenciennes.

Targeted Alpha Therapy with lead-212 combines the natural ability of biological molecules to target cancer cells with the short-range cell-killing capabilities of lead-212 generated alpha emissions. The development of these therapies has long been hampered by the difficulty to manufacture on an industrial scale. The construction of Orano Med's ATLab Valenciennes is therefore a major step towards making these promising new treatments available to cancer patients with high unmet needs. 

ATLab Valenciennes, with over 3,000 m² of floor space, will represent an investment of €29 million and will create 25 direct jobs. It will focus on the production of lead-212 therapies developed by Orano Med and their distribution in Europe. Orano Med is due to inaugurate a similar facility this year in Indianapolis to serve the US market. 

This combined capacity will enable Orano Med to manufacture 10,000 doses a year as of 2025, with the aim of producing ten times that number by the end of the decade. Given the short half-life of lead-212 (10.6 hours), the drugs need to be produced close to hospitals. The construction of further ATLabs is therefore envisaged to meet patients' needs worldwide. 

Guillaume Dureau, the Orano Group's Senior Executive Vice-President Projects & Innovation R&D and Nuclear Medecine, commented: "The ATLab in Onnaing is a very important step in our development strategy and is situated at the very heart of the industrial fabric of the Valenciennes metropolitan area and the Hauts-de-France region. The expansion of our production capacity in the radiopharmaceutical field is part of a drive to revitalize our country’s industrial and economic fabric."

Julien Dodet, CEO of Orano Med: "We are convinced that radioligand therapies will soon become an essential tool in the fight against cancer. As the Phase II clinical trial of our most advanced drug AlphaMedix nears completion, we are building a global industrial platform to ensure the large-scale production and distribution of these potential treatments."

The construction of ATLab Valenciennes is supported by the Hauts de France region and the Valenciennes metropolitan area. The project has also been selected under the France 2030 plan following the call for "Industrialization and health capacities 2030" projects and will receive public support of almost €3.8 million. By using a variety of biological vector technologies to target cancer cells, Orano Med's activities are perfectly aligned with the French national biotherapies - bioproduction acceleration strategy coordinated by the Health Innovation Agency (AIS), which has bringing new cancer biotherapies to market by the end of the decade as one of its key objectives.